Injectable drug delivery is considered to be one of the most effective routes of administration due to the speed and effectiveness of delivery to the target, and recent developments have improved the patient experience. The global injectable drug delivery market continues to grow and technology is advancing. This, coupled with the ever-changing regulatory requirements, means that it is imperative for companies to stay abreast of the latest developments and challenges within the industry in order to remain compliant, as well as gaining a competitive edge.
This seminar has been designed to provide all those working in the industry with the latest information on the next generation of injectable drugs and devices and an update on recent trends, technologies and applications. It will also be a great opportunity to meet industry leaders, as well as like-minded professionals, and share common experience and best practice.
Attending this two-day seminar, presented by experts in the field, will:
Previous Exhibitors Include:
Exhibition opportunities are available. Please contact Customer Services on +44 (0)20 7749 4730
or contact us through our contact form.
This is a key seminar for all those working in the parenteral delivery area, including:
Latest developments for injectable drug delivery solutions
Recent advances in large-volume injection
Developments in technology with injectables – digitalisation and smart technology
Digital design in development of injectable systems
Case study: Connected needle-free technology
Assessing injection site pain
Betwixt and between – managing the interface between PFS and autoinjector
Interactive panel discussion: Next generation innovations in drug delivery
Moderator: Dr Gregory Berman
Panellists: Ian Thompson, Neil Williams, Markus Bauss, Dr Thomas Schoenknecht
The EU regulatory framework for injectable delivery systems
Human factors validation – when is usability testing not required?
Sustainability – its impact on self-care drug delivery
Extractables and leachables (E&L) in injectable drug products
Pre-filled syringes in a nutshell
The relationship between the ICH guidelines for impurities and E&L thresholds
Interactive panel discussion: The future with smart injection devices
Moderator: Dr Gregory Berman
Panellists: Ian Thompson and Dr Thomas Schoenknecht
Chair’s closing remarks
Gregory Berman is an Independent Consultant and Director of Cantab Innovations Ltd. Previously he was Head of the Medical Group at Kinneir Dufort, an award-winning research, innovation, design and product development company, with over 30 years’ experience helping companies discover, create, develop and realise tangible new products, brands and experiences. He helps clients in the life-science, medical and healthcare sectors to develop products in complex situations, optimise life-science R&D and exploit technology strategically.
He led the design and development of SmartJect™; an autoinjector which automatically retracts the needle and was launched by J&J in 2010 with an important next-generation drug.
Worked with Chrono Therapeutics, helping to develop their SmartStop™ based device, the world’s first programmable, wearable transdermal smoking cessation therapy.
Participated in a detailed design review of an autoinjector being developed by a leading pharmaceutical company for a new drug.
Undertook the Voice of Customer study for a leading biopharmaceutical company, as the starting point for developing high volume parenteral delivery devices for lifesaving immunotherapies.
Undertook a technology survey for a company interested in needle-free, transdermal, micro-needle, electroporation and iontophoresis drug delivery devices.
Ian Thompson has been Vice President Business Development, Delivery Systems with Ypsomed AG since 1995. He has had a number of roles in key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems. He studied biochemistry and biotechnology in the UK from 1979-1983 and has worked in medical device companies since moving to Switzerland in 1990. Following the successful development and launch of a range of new pen and autoinjector custom products, Ypsomed Delivery Systems’ continues to focus on the development of next generation pen, autoinjector and bolus injector technologies.
Dr. Patrick Anquetil is Portal Instrument’s Chief Executive Officer. He brings more than 18 years of experience in nanotechnology, including extensive knowledge in the areas of cleantech, material science, and instrumentation.
From 2009 to 2012, he was co-founder and director of strategic and process planning for SynapDx Corporation, where he had responsibility for development of the company’s business and operational plans as well as securing $9 million in Series A funding. He began his career as a science and nanotechnology equity research analyst at Susquehanna International Group, authoring and marketing nanotechnology industry and equity research reports to hedge funds and portfolio managers. He holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard University, and a master’s degree from the ETH in Zurich and the University of Tokyo. His work has appeared in numerous peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC among others.
Neil is the Head of Connected Health and Director of Front-End Innovation for Phillips-Medisize, based in Cambridge UK. Neil consults for BioPharma clients, innovating and executing strategies to enhance stakeholder engagement through connected devices and service design. He has over 22 years’ commercial experience covering medical devices, telemetry, digital imaging, clinical decision support, secure mobile working, patient engagement and health analytics for businesses including Philips Healthcare, Microsoft, Elsevier Health Sciences, Hospira, Map of Medicine and ZOLL. Prior to Neil’s commercial career he trained at Leicester University Hospitals in Operating Department Practice and was Faculty for numerous Advanced Life Support programs having qualified in the UK and United States.
Chris Muenzer is a Senior Device Technology Manager at Novartis in Basel, Switzerland. He has almost 20 years of development experience with a focus on drug delivery devices and has filed several patents in the field. At Novartis, Mr. Muenzer leads a team supporting injectable delivery systems for Novartis’ diverse portfolio of drugs. In addition to his work at Novartis, he is active on the ISO working group for injection devices. Mr. Muenzer holds a BSME from Carnegie Mellon University in Pittsburgh, Pennsylvania in the US.
Jeffrey Philippson is a specialist in testing and evaluation of parenteral drug delivery devices with PA Consulting in Cambridge, UK and leads the PA Injection Science team. Jeffrey applies statistics and data analysis to the development and evaluation of drug delivery devices, with a particular focus on autoinjectors, pen-injectors and infusion pumps. He is an expert in design input creation, test method development and validation, and design verification processes. He holds a PhD in Experimental Physics from Queen’s University (Kingston, ON, Canada).
Lee Wood is Co-founder and CEO of medHF and specialises in the application of Human Factors Engineering to the medical device development process. medHF support manufacturers to develop safe, usable and approvable devices by delivering high quality Human Factors services. Lee is an expert in supporting manufacturers to effectively navigate and successfully meet regulatory expectation. Previously he was Head of Human Factors Engineering with Roche and before that Human Factors/Principal Scientist with Novartis.
|10-11 Mar 2021|
|10-11 Mar 2021||Venue not yet confirmed||
+ VAT @ 20.00%
|Online registration unavailable: this date is nearing full capacity; please call us on 020 7749 4730 to register.|